CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: GlobeNewswire
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treatment centers (ATCs) activated globally for CASGEVY and approximately 40 patients have had cells collected across all regions as of mid-October- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX112™ targeting CD19, in B-cell malignancies and systemic lupus erythematosus- -Two clinical trials are ongoing for next generation CAR T product candidate, CTX131™, targeting CD70, in solid tumors and hematological malignancies- -Company plans to provide an update on the Phase 1 dose escalation study of CTX112 in B cell malignancies at the American Society of Hematology (ASH) 2024 Annual Meeting- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and LPA, respectively- -Clinical trial ongoing for CTX211™
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- 3 Monster Stocks in the Making [Yahoo! Finance]Yahoo! Finance
- Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 11/13/24 - Form 4
- 11/12/24 - Form 144
- 11/5/24 - Form 10-Q
- CRSP's page on the SEC website